Using oligonucleotide sequences, which are specific for the HER2 promoter, the ability of nuclear extracts from non-treated, primary breast cancer cell cultures to bind to the DNA response element was compared to cells treated with bFGF and EGF (Figure 1B). The gene discussed is ERBB2; the disease is breast carcinoma.